We advance precision diagnostics with a rich pipeline of proprietary biomarker discoveries
We aim to improve clinical outcomes and shorten the drug development process by leveraging single-cell technologies and our proprietary AI platform ScaiVision.
Using our cluster-free, unbiased, and highly sensitive AI platform, we have built unique capabilities to discover new clinically-relevant biomarker signatures with diagnostic or stratification potential for clinics in several complex indications.
Scailyte provides a rapid and efficient end-to-end pipeline for extracting relevant biosignatures from single-cell data related to efficacy, toxicity or to the mode of action of therapeutics. These discoveries offer the basis for companion diagnostics and in-vitro diagnostic assay prototypes on common platforms in the clinic.
We applied ScaiVision AI to single-cell proteomics data (CyTOF) to identify biomarker signatures for the differential diagnosis of CTCL vs. Atopic Dermatitis (AD).
We identified cells and a protein signature allowing highly specific specific and sensitive detection of CTCL
ScaiVision does not operate as a “black box”, so we could use its learning features to simplify this complex single-cell protein signature and translate it into a simple, inexpensive flow cytometry diagnostics assay.
Remarkably, the translation from 36-parameter CyTOF to 9-parameter flow cytometry didn’t affect the clinical performance because, with the help of ScaiVision, we selected the minimal set of informative markers, achieving over 95% sensitivity, largely outperforming existing molecular diagnostic tests
Use Case:
Patient stratification: ScaiVision predicts ICI response at baseline in metastatic NSCLC (Non Small Cell Lung Cancer)
